Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed in previously treated metastatic gastric cancer
NCT01953419Phase 2
Key facts
- Status
- Completed
- Start
- Sep 2010
- Primary completion
- Dec 2013
- Countries
- 1
- Sponsor
- Sun Yat-sen University
- Modality
- Small Molecules
- Drugs
- pemetrexed
- Conditions
- gastric cancer (GC)
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in gastric cancer (GC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 6 weeks. Started Sep 2010; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Treatment group
Pemetrexed 500mg/m2 every 21 days
03
Who it enrols
Patients with histologically confirmed inoperable or metastatic adenocarcinoma of the stomach or GEJ, aged 18-80, ECOG 0-2, with at least one prior chemotherapy regimen and adequate organ function.
04
Endpoints
Primary
Objective Response Rate
Beyond the preview
Go deeper on NCT01953419.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01953419.